Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | HTR1F | P30939 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12975620 | 0.85 | HTR1F (0.55) | HTR1FHPGDSYKSMN1; SMN2PARP1 | |
| SCHEMBL4770372 | 0.76 | DRD2 (0.47) | — | |
| SCHEMBL4791557 | 0.72 | DRD2 (0.54) | BRAF | |
| SCHEMBL5660577 | 0.71 | MDM4 (0.50) | — | |
| SCHEMBL410932 | 0.71 | CNR2 (0.49) | SMN1; SMN2PARP1 | |
| SCHEMBL23103361 | 0.71 | TLR9 (0.42) | — | |
| SCHEMBL5515435 | 0.71 | HTR2C (0.52) | — | |
| SCHEMBL4764984 | 0.71 | NAMPT (0.56) | — | |
| SCHEMBL19699466 | 0.71 | ADORA3 (0.40) | ADORA1ADORA3ADORA2ACCNA2CDK2 | |
| SCHEMBL6027438 | 0.71 | ADORA1 (0.54) | ADORA1HTR1FHPGDSYKSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-20060217418-A1 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2006-09-28 | — | — | US | disclosed |
| US-7067534-B1 | Substituted anilinic piperidines as MCH selective antagonists | H. LUNDBECK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| US-20060084649-A9 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2006-04-20 | — | — | US | disclosed |
| CN-1735595-A | Substituted alkyl amido piperidines | LUNDBECK & CO AS H (DK) | 2006-02-15 | — | — | CN | disclosed |
| CN-1671386-A | Substituted anilinic piperidines as MCH selective antagonists | LUNDBECK & CO AS H (DK) | 2005-09-21 | — | — | CN | disclosed |
| EP-1411942-A4 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040186103-A1 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-09-23 | — | — | US | disclosed |
| EP-1411942-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | Synaptic Pharmaceutical Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| WO-2003004027-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | XIAP 2518/4885BIRC2 3832/4885ADORA1 13/4885 |
| US-20060084649-A9 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | XIAP 4427/4885BIRC2 4180/4885ADORA1 16/4885 |
| US-20060217418-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | XIAP 4427/4885BIRC2 4180/4885ADORA1 16/4885 |
| US-20040186103-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | XIAP 4427/4885BIRC2 4180/4885ADORA1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.